报道了在碱性条件下由嘧啶和四嗪直接合成嘧啶并[4,5- d ]哒嗪的方法。去质子化的取代的5-卤代嘧啶易于通过复杂的反应途径以高度区域选择性的方式与各种取代的四嗪发生反应,这得到了DFT计算的支持。该机理导致通过经验观察到的区域异构体而不经过可能的戊炔中间体。关于5-卤代嘧啶的这些结果导致开发了基于6-卤代嘧啶的相反的区域异构体的制备方法。
Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1
作者:Andrew Fensome、Catherine M. Ambler、Eric Arnold、Mary Ellen Banker、James D. Clark、Martin E. Dowty、Ivan V. Efremov、Andrew Flick、Brian S. Gerstenberger、Roger S. Gifford、Ariamala Gopalsamy、Martin Hegen、Jason Jussif、David C. Limburg、Tsung H. Lin、Betsy S. Pierce、Raman Sharma、John I. Trujillo、Felix F. Vajdos、Fabien Vincent、Zhao-Kui Wan、Li Xing、Xiaojing Yang、Xin Yang
DOI:10.1016/j.bmc.2020.115481
日期:2020.5
Herein, we disclose a new series of TYK2/ JAK1 inhibitors based upon a 3.1.0 azabicyclic substituted pyrimidine scaffold. We illustrate the use of structure-based drug design for the initial design and subsequent optimization of this series of compounds. One advanced example 19 met program objectives for potency, selectivity and ADME, and demonstrated oral activity in the adjuvant-induced arthritis rat model.
GACEK, M.;UNDHEIM, K., ACTA CHEM. SCAND., 1985, 39, N 8, 691-696